



ASX ANNOUNCEMENT

1 July 2009

More VitroGro® Patents Granted in South Korea and Australia

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** announced today that two more of the family of VitroGro® patents have been granted in Australia and South Korea.

This adds to the multiple VitroGro® patents already granted in the USA, Australia, New Zealand and South Africa.

The VitroGro® intellectual property position has also been strengthened by a new international patent application that further defines and protects the ways in which VitroGro® accelerates wound healing. This new patent will be pursued in the same international territories as the rest of the VitroGro® family of patents ie. USA, Canada, EU, Japan, South Korea, Hong Kong, China, India, South Africa, Australia and New Zealand.

The CEO, Dr Steven Mercer said, "The continued success in the granting of VitroGro® patents around the world is a practical endorsement of the technology and reinforces the commercial value of the VitroGro® IP portfolio and the company."

Further information: Dr Steven Mercer
 CEO, Tissue Therapies Limited
 Telephone: 07 3839 9938

 Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic ulcers and burns,

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com